Insight Molecular Diagnostics Inc. Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic
Insight Molecular Diagnostics Inc. (IMDX) reported Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic of -$2.93 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic · last filed 2025-03-24
- Insight Molecular Diagnostics Inc. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-12-31 was $0.00.
- Insight Molecular Diagnostics Inc. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-09-30 was $0.00.
- Insight Molecular Diagnostics Inc. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-06-30 was -$2.92M.
- Insight Molecular Diagnostics Inc. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-03-31 was -$2.50K.
- Insight Molecular Diagnostics Inc. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2023 was -$2.93M.
| Period end | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 3 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 3 month as first filed | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 6 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 9 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 derived: sum of 2 quarters · filed 2025-03-24 | -$2.92M derived: sum of 3 quarters · filed 2025-03-24 | -$2.93M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.92M derived: sum of 2 quarters · filed 2024-11-12 | -$2.93M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.93M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$2.50K 10-Q · filed 2024-05-15 | -$2.50M 10-Q · filed 2023-05-15 | |||
| 2022-03-31 | -$6.88M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |